| Analyte | MW (kDa) | LLOQ | IS type | Sample Volume (uL) | Injection Volume (uL) | Sample Preparation | LC (Sorbent; L*id; particle size) |
| PTH 1 - 34 | ~4.1 | 15 pg/mL | SIL-IS | 150 | 30 - 40 | PPT | C18; 100 mm × 2.1 mm, 1.7 μm |
| Semaglutide | ~3.1 | 3 ng/mL | Analog | 100 | NA | PPT | C18; 50 mm × 2.1 mm, 1.8 μm |
| BNP (1 - 32) | ~3.4 | 1.4 pg/mL | SIL-IS | 1000 | 10 | LAC | C18; 50 mm × 150 μm, 1.8 μm |
| GPL1 (7 - 36), GLP1 (9 - 36), OXM, Glucagon | ~3.3 (GPL1(7 - 36)), ~3.1 (GLP1(9 - 36)), ~4.4 (OXM), ~3.5 (Glucagon) | 0.78 pM | SIL-IS | 500 | 16 | LAC | C18; 50 mm × 150 μm, 1.7 μm |
| Liraglutide | ~3.7 | 100 ng/mL | Analog | 25 | 5 | PPT | C4; 50 mm × 2.1 mm, 1.8 μm |
| PYY (3 - 36) | ~4.0 | 2 nM | None | 30 | 5 | PPT | C12; 50 mm × 2.0 mm, 4 μm |
| Sermorelin | ~3.3 | 50 pg/mL | Analog | 100 | 1 | LAC | C18; 100 mm × 75 μm，3 μm |
| Glucagon | ~3.4 | 15 pg/mL | SIL-IS | 400 | 40 | PPT + SPE | C18; 100 mm × 2.1 mm, 1.7 μm |
| GLP1 (7 - 36) | ~3.3 | 25 pg/mL | SIL-IS | 400 | 40 | PPT + SPE | C18; 100 mm × 2.1 mm, 1.7 μm |
| Insulin glargine | ~6.1 | 16 pM (0.1 ng/mL) | SIL-IS | 500 | 20 | LAC | C4; 50 mm × 2.1 mm, 1.7 μm |
| Sun flower trypsin inhibitor (SFTI) | ~1.7 | 0.125 ng/mL | None | 30 | 5 | PPT | C18; 100 mm × 2.1 mm, 5 μm |
| Variegin | ~3.6 | 21.6 nM | SIL-IS | 200 | 20 | SPE | C18; 50 mm × 2.1 mm, 5 μm |
| Glucose- responsive insulin (GRI)* | ~7.1 | 100 pM (1 ng/mL) | Analog | 40 | 10 | LA | C4; 50 mm × 2.1 mm, 1.7 μm |
| Glucose- responsive insulin (GRI)** | ~7.1 | 500 pM (0.4 ng/mL) | Analog | 200 | 10 | SPE | C4; 50 mm × 2.1 mm, 1.7 μm |
| Liraglutide | ~3.7 | 10 ng/mL | Analog | 50 | 5 | PPT | C18; 50 mm × 150 μm, 1.8 μm |